AVITA Medical (ASX:AVH) has taken a significant step in strengthening the United States’ emergency medical preparedness, securing a long-term agreement with the Biomedical Advanced Research and Development Authority that places its regenerative skin technology at the centre of the national burn response strategy.
The ten-year contract, valued at up to $25.5 million, is designed to ensure that critical treatment resources are immediately available when large-scale burn incidents occur, a scenario where speed and scalability can determine survival outcomes.
RECELL, AVITA's proprietary Spray On Skin technology, uses a patient’s own cells to accelerate healing.
Under the terms of the agreement, thousands of RECELL units will be maintained in a state of readiness, able to be deployed rapidly across the country whenever federal authorities activate emergency response protocols.
The company said a portion of the funding is allocated to maintaining constant access and operational preparedness, while the remainder is tied to procurement options that can be activated as needed over the decade. This flexible framework allows the government to respond proportionately to events while ensuring the underlying capability remains in place.